D uring the past 30 years, survival rates for patients with laryngeal cancer have not improved, and some investigators have raised concerns that 5-year Surveillance, Epidemiology, and End Results (SEER) program survival rates for patients with advanced cancer have actually declined with the introduction of chemotherapy and radiotherapy treatment strategies for organ preservation. [1] [2] [3] Diseasespecific survival (DSS) rates for limited cancers (stages I and II) typically range from 60% to 90%, but the best reported rates for patients with advanced cancers (stages III and IV) range from only 50% to 60%. [4] [5] [6] For patients with limited disease, laser-assisted endoscopic resection as an alternative to definitive radiotherapy or hemilaryngectomy has been widely adopted for patients with stages I and II laryngeal cancer and selected patients with stage III laryngeal cancer. 7, 8 However, the optimal treatment approach for patients with advanced laryngeal cancer who face total laryngectomy remains unclear, and controversy exists in recommending a primary surgical vs nonsurgical approach. 6, [9] [10] [11] [12] [13] For patients with advanced disease, the Department of Veterans Affairs initiated the first randomized trial comparing a standard surgical approach (total laryngectomy) with an innovative approach that incorporated neoadjuvant chemotherapy followed by definitive radiotherapy.
14 Integrated into this experimental strategy was early laryngectomy for patients who were nonresponders after multiple cycles of neoadjuvant chemotherapy. Although the results of the Department of Veterans Affairs trial failed to demonstrate a survival advantage for the experimental treatment regimen, twothirds of the patients were able to avoid laryngectomy, without any significant decrease in survival or quality of life, compared with patients randomized to total laryngectomy. 14,15 Two subsequent randomized trials testing the Department of Veterans Affairs trial approach confirmed these results 16, 17 and showed that the highest larynx preservation rates were achieved with concurrent chemoradiotherapy compared with a sequential neoadjuvant approach or radiotherapy alone.
17
Large meta-analyses have documented better survival with combinations of chemotherapy and radiotherapy over radiotherapy alone 18 and better results for concurrent chemoradiotherapy compared with neoadjuvant treatment. 19 However, more recent randomized trials have failed to show improvements in survival comparing various intensive neoadjuvant vs sequential or concurrent chemoradiotherapy approaches.
20-22
Based on these cumulative experiences, a standard treatment approach of concurrent chemoradiotherapy has been widely adopted as the preferred alternative to total laryngectomy for patients with advanced laryngeal cancer who are seeking larynx preservation. 23 Unfortunately, 5-year overall survival (OS) rates remain less than 50%. 4, 24 Because survival rates in trials with concurrent chemoradiotherapy have not improved but toxic effects are increased, concerns have been raised about the wisdom of potentially preserving a nonfunctional larynx, especially in patients with T4a category cancers where significant dysfunction and long-term aspiration could be a potential problem. In fact, T4a category cancers are often considered a contraindication for chemoradiotherapy. 10 Because of these various results, neoadjuvant chemotherapy strategies to select patients for organ preservation have remained an investigative option.
25
Largely ignored in the past development of organ preservation treatment strategies has been the evidence that cancers showing a rapid response to neoadjuvant chemotherapy have a favorable response to subsequent radiotherapy and improved survival. 26 In fact, the most consistent observation in all trials of neoadjuvant chemotherapy has been the association between tumor response to chemotherapy and favorable prognosis. To further test the concept of using a response to chemotherapy as a basis to individualize therapy for patients with stage III or IV cancer who face total laryngectomy, our group conducted a series of phase 2 trials using a single cycle of cisplatin-based neoadjuvant chemotherapy to select patients for subsequent radiotherapy. [26] [27] [28] Responders (>50% primary tumor reduction) went on to receive a definitive course of chemoradiotherapy (concurrent cisplatin) and nonresponders underwent immediate total laryngectomy followed by adjuvant radiotherapy. The results unexpectedly demonstrated very high 5-year, DSS (82%; 95% CI, 72%-89%) in an unselected cohort of 97 patients with very advanced disease (including T4a category) that was superior to outcomes that had been achieved in our group's previous trials. 27, 28 The favorable survival rate was evident in both the group of responders selected for subsequent chemoradiotherapy and the nonresponder group undergoing surgical total laryngectomy. Typically, patients in whom multicycle neoadjuvant chemotherapy fails show a poor rate of survival; thus, these results were unexpected and exciting and demanded validation. Following these trials, we adopted a standard institutional approach to patients with advanced laryngeal cancer that offered all patients an initial cycle of neoadjuvant therapy and then a definitive treatment decision as to total laryngectomy vs definitive chemoradiotherapy based on the neoadjuvant chemotherapy response. For patients refusing chemotherapy or those who were medically unfit, primary total laryngectomy was recommended. Some patients were offered primary concurrent chemoradiotherapy or radiotherapy alone if they refused the possibility of selection for total laryngectomy or wanted exclusively nonsurgical treatment.
To determine outcomes of these individualized treatment decision criteria, including bioselection with neoadjuvant chemotherapy, we performed a retrospective cohort analysis of OS and DSS for all patients with previously untreated laryngeal cancer seen at the University of Michigan, Ann Arbor, from January 1, 2002, to December 31, 2012.
Methods

Patient Population and Treatment Regimens
From January 1, 2002, to December 31, 2012, a total of 293 patients with laryngeal cancer were evaluated and enrolled in our epidemiology project that assessed correlations between treatment outcomes and clinical, genetic, and health behavior characteristics. Of these, 191 (77.3%) were men; mean (SD) age was 59.6 (10.4) years. The University of Michigan Health System institutional review board approved the study and the patients provided written informed consent. Patients did not receive financial compensation.
A total of 46 (15.7%) patients were excluded from the present analysis because they received palliative treatment (n = 27), refused all treatment (n = 14), were previously treated (ie, recurrent cancer), or histologic testing did not show squamous cell carcinoma (n = 5). This left a total of 247 evaluable cases consisting of 115 (46.6%) glottic and 132 (53.4%) supraglottic cancers. Cohort clinical characteristics and treatments are reported in eTable 1 in the Supplement. The Adult Comorbidity Evaluation-27 grades specify diseases and conditions into 1 of 3 levels of comorbidity: grade 1 (mild), grade 2 (moderate), or grade 3 (severe), according to the severity of individual organ decompensation and prognostic impact. 29 Once the patient's individual diseases or comorbid conditions were classified, an overall comorbidity score (none, mild, moderate, or severe) was assigned based on the highest-ranked single ailment. In the cases in which 2 or more moderate ailments occurred in different organ systems or disease groupings, the overall comorbidity score was designated as severe. , or carboplatin, AUC 6) was used for 50 patients (32.7%) refusing neoadjuvant chemotherapy or for logistical issues. Primary laryngectomy was used in 26 patients (17.0%) for severely compromised larynx or for 6 patients (3.9%) who were possible candidates for larynx preservation with a supraglottic laryngectomy (eFigure 1 in the Supplement). All patients were discussed at a multidisciplinary tumor board meeting before treatment recommendations, and all patients were monitored closely after treatment by our team for possible recurrence. Patients receiving chemoradiotherapy at outside facilities had treatment plans reviewed and received follow-up by our treatment team. All patients were seen weekly in our medical oncology and radiotherapy oncology clinics during their treatments with chemoradiotherapy. Median follow-up for all patients was 48 months.
Statistical Analysis
Overall survival and DSS times were defined from the date of diagnosis to death or last follow-up. Deaths from causes other than cancer were censored at the date of death for DSS analysis. The Kaplan-Meier method was used to estimate OS and DSS rates with 95% CIs of the point estimates using a log-log transformation. Multivariable analyses were carried out using Cox proportional hazards regression models within the patients with limited (stage I or II) and advanced (stage III or IV) cancer separately. In patients with limited-stage cancer, we also performed Cox proportional hazards regression model multivariable analyses after excluding 9 patients with in situ carcinoma, leaving 85 patients with limited-stage cancer (25 surgery and 60 chemoradiotherapy or radiotherapy) and tested for differences in OS and DSS by treatment, controlling for stage (I vs II) in the model.
Among the 153 patients with stage III or IV cancer, patient and tumor characteristics differed between treatment approaches; therefore, we performed propensity scoreadjusted multivariable Cox proportional hazards regression model analyses for OS and DSS comparing the 3 treatment approaches. Two separate analyses were carried out comparing (1) neoadjuvant bioselection with definitive chemoradiotherapy and (2) neoadjuvant bioselection with definitive surgery. Propensity scores were derived from a logistic regression model for the probability of neoadjuvant therapy compared with definitive chemoradiotherapy (analysis 1) or definitive surgery (analysis 2). The final propensity models for neoadjuvant selection included age, sex, comorbidity, current smoking, tumor stage, disease subsite, and year of diagnosis, and resulted in C statistics of 0.76 and 0.72 for the chemoradiotherapy comparison and surgery comparison, respectively. Propensity scores were used to create weighted data sets using inverse probability of treatment weighting, and results for propensity-weighted Cox proportional hazards regression models among the patients with stage III or IV cancer are reported. 30 In addition, sensitivity analyses were performed using the propensity information in different ways. We performed a second weighted Cox proportional hazards regression model that trimmed extreme propensity weights (<0.2 or >5.0) and also Cox proportional hazards regression models that stratified the baseline hazard function by propensity scores grouped in quintiles. These sensitivity analyses yielded the same conclusions (although slightly different point estimates) as the reported inverse probability of treatment weighting Cox proportional hazards regression model multivariable results. All analyses were performed using SAS software, version 9.4 (SAS Institute Inc) for Windows. Data analysis was completed December 1, 2015.
Results
Overall and Disease-Specific Survival
Estimated 5-year OS for the combined cohort was 75% (95% CI, 68%-81%) and ranged from 81% (95% CI, 69%-89%) for stages I and II to 72% (95% CI, 63%-79%) for stages III and IV disease. Estimated 5-year DSS for the entire cohort was 83% (95% CI, 77%-88%) and, for patients with stage III or IV disease, DSS was 78% (95% CI, 69%-84%) compared with 92% (95% CI, 83%-97%) for patients with limited disease. Estimated 5-year OS and DSS for the patients with advanced disease (stages III and IV) treated with neoadjuvant bioselection were 76% (95% CI, 63%-85%) and 79% (95% CI, 67%-88%), respectively. The overall 5-year OS for patients with advanced disease treated with definitive surgery was 78% (95% CI, 55%-90%). There were no significant differences in OS according to glottic vs supraglottic disease subsite or comparing stages I and II with stages III and IV disease. However, when pairwise comparisons by disease stage were performed by log-rank testing, results for stage I compared with stage IV differed significantly for DSS but not for OS ( Figure 1 ). All other comparisons failed to find significantly different survival rates for patients with advanced disease compared with those with limited disease ( Figure 1 ). When all patients were combined, survival outcomes differed by treatment and favored primary surgery. Overall survival was similar for patients treated with radiotherapy alone or chemoradiotherapy and was significantly inferior to OS in patients treated with primary surgery (Figure 2 ). The improved survival associated with primary surgery was due in part to results achieved for patients with limited disease, where primary surgery resulted in very good survival and 100% larynx preservation compared with radiotherapy. The surgery alone group benefited by inclusion of 9 patients who underwent endoscopic resections for carcinoma in situ. . Organ preservation was achieved in 94% of the patients, with none of the surgical patients requiring total laryngectomy; 5 (10%) of 50 patients receiving radiotherapy alone and 1 individual receiving (8%) chemoradiotherapy eventually required total laryngectomy. Five-year OS for patients with limited disease was significantly better for primary surgery compared with radiotherapy and chemoradiotherapy (97% vs 71%). The increase in OS survival proportion was 26% with (95% CI, 4%-48%). There was a 7% difference in DSS (97% vs 90%), which did not reach statistical significance (95% CI of absolute difference, −17% to 31%) (eFigure 2 in the Supplement). The outcome differences were confounded by differences in patient characteristics, such as T class. Surgically treated patients were significantly more likely to have lower stage disease. After excluding 9 patients with in situ carcinoma and controlling for stage in a multivariable Cox proportional hazards regression model, the survival advantage of surgery remained but was not statistically significant for either OS or DSS (hazard ratio [HR], 0.17; 95% CI, 0.02 to 1.41; and HR, 0.70; 95% CI, 0.07 to 7.739; respectively).
Advanced Laryngeal Cancer (Stage III or IV) Treatment and Outcomes
Initial treatment for 153 patients with advanced disease included primary surgery (32 [20.9%]; 26 total laryngectomy and 6 supraglottic laryngectomy), neoadjuvant chemotherapy for treatment selection (71 [46.4%]), or definitive concurrent chemoradiotherapy (45 [29.4%]) and radiotherapy alone (5 [3.3%]) (eFigure 1 in the Supplement). The neoadjuvant bioselection group had 11 patients referred for total laryngectomy based on poor tumor response and 60 patients referred for definitive chemoradiotherapy. A total of 13 additional laryngectomies were eventually required among the patients referred for chemoradiotherapy after neoadjuvant selection and for only 4 patients after definitive chemoradiotherapy.
Overall 5-year survival was 72% (95% CI, 63%-79%) for the entire cohort of patients with advanced disease and varied from 76% (95% CI, 63%-85%) for neoadjuvant bioselection treatment to 61% (95% CI, 44%-75%) for primary chemoradiotherapy. Overall 5-year OS for the surgery group of patients with advanced disease was 78% (95% CI, 55%-90%). Five-year DSS was 78% (95% CI, 69%-84%) for all patients with advanced disease and varied from 91% (95% CI, 67%-98%) for primary surgery to 79% (95% CI, 67%-88%) for neoadjuvant bioselection and 66% (95% CI, 48%-79%) for chemoradiotherapy. Compared with survival by planned initial treatment, no significant pairwise differences were noted in OS, but DSS was higher for primary surgery compared with chemoradiotherapy ( Figure 3) . By Cox proportional hazards regression analysis, OS and DSS were significantly improved in the neoadjuvant bioselection group compared with the definitive chemoradiotherapy and radiotherapy without induction selection groups (HR, 0.36; 95% CI, 0.16-0.81; and HR, 0.37; 95% CI, 0.16-0.90, respectively) after controlling for age, stage (III vs IV), comorbidities, and current smoking (eTables 5 and 6 in the Supplement). Furthermore, OS and DSS for the neoadjuvant bioselection group were similar to those of the surgery group (HR, 1.33; 95% CI, 0.46-3.38; and HR, 3.32; 95% CI, 0.70-15.88, respectively) (eTables 7 and 8 in the Supplement).
When patients with advanced disease were grouped by T classification, 32 (54.2%) of patients with T4a category cancers were treated with neoadjuvant bioselection and 12 patients (52.1%) with T1 or T2 category primaries underwent definitive chemoradiotherapy. Only 12 (16.9%) T3 category cases and 16 (27.1%) of T4 category cases underwent primary surgery (eTable 2 in the Supplement). When analyzed by both tumor site and stage, it was evident that patients with stage IV disease were more likely to have neoadjuvant bioselection with equal proportions of glottic and supraglottic sites. However, 
Neoadjuvant Bioselection Adjusted for Patient and Tumor Characteristics
Because treatment selection was nonrandom and subject to patient and physician preferences, we further explored differences in outcomes to determine whether there was benefit from neoadjuvant bioselection compared with other treatments by performing a propensity score-adjusted comparison to account for differences in patient and tumor characteristics that might have influenced treatment decisions. Among all 153 patients with stage III or IV disease, 2 propensity scoreadjusted multivariable Cox proportional hazards regression model analyses were performed for DSS and OS comparing neoadjuvant bioselection with definitive surgery and definitive chemoradiotherapy. The propensity score models were derived from a logistic regression model for the probability of receiving neoadjuvant therapy. The final propensity models for neoadjuvant bioselection included age, comorbidity score, current smoking, stage, disease subsite, and year of diagnosis for both comparisons. In Cox proportional hazards regression models of propensity-weighted data sets, DSS differed between the 3 treatment approaches.
In the propensity analysis, we found that DSS and OS were significantly improved in the neoadjuvant bioselection group compared with the definitive chemoradiotherapy and radiotherapy groups (HR, 0.48; 95% CI, 0.29-0.80; and HR, 0.48; 95% CI, 0.30-0.78, respectively). We also found that DSS for the definitive surgery group was significantly better compared with the neoadjuvant bioselection group (HR, 0.14; 95% CI, 0.14-0.82), but we failed to find evidence for better OS in the surgery group (HR, 0.84; 95% CI, 0.46-1.53). The results of all treatment comparisons remained statistically significant or nonsignificant when we adjusted for age, stage, tumor site, comorbidities, and smoking for double robustness in our analysis models. In the doubly robust models, OS was again better for the neoadjuvant bioselection approach (HR, 0.43; 95% CI, 0.26-0.69) compared with chemoradiotherapy and was similar to survival for the primary surgery group (HR, 0.70; 95% CI, 0.37-1.34) ( Table 1 and Table 2 ). The propensityadjusted analyses confirmed the findings resulting from simple Cox proportional hazards regression univariable and multivariable models of treatment approach.
We next compared the potential benefit of primary surgery vs standard chemoradiotherapy among the 81 patients with stage III or IV disease who were not selected for neoadjuvant bioselection. We observed no factors other than tumor stage and subsite that influenced the treatment choice. Among these patients, individuals with glottic and stage IV tumors were more likely to receive surgery. Adjustment for these factors in a stratified Cox proportional hazards regression model showed that surgical treatment was associated with a decreased risk of disease-specific death both before and after adjusting for age, comorbidities, and current smoking (HR, 0.11; 95% CI, 0.02-0.56; and HR, 0.14; 95% CI, 0.03-0.68, respec- 
Functional Larynx Preservation
It is increasingly clear that preservation of laryngeal function is more important than simply preserving anatomical structure for assessing overall success. Thus, the status of larynx function as reflected by the presence of a feeding gastrostomy tube or tracheostomy at 1 year was recorded. Of the 94 patients with limited-stage cancers, total laryngectomy as a salvage procedure for local recurrence was necessary in 6 (6.4%) patients (5 following a failure of radiotherapy and 1 after failure of chemoradiotherapy) and none was required after initial primary surgical resection. The overall organ preservation rate was 94%. Only 1 of the limited patients required a tracheostomy and gastrostomy tube at 1 year. For the 153 patients with advanced disease, primary total laryngectomy was performed in 26 (17.0%) patients and organ-preserving surgery (supraglottic laryngectomy) was possible in 6 (3.9%) patients. Among these surgically treated patients, 2 had a feeding gastrostomy tube at 1 year. Of 50 patients treated with concurrent chemoradiotherapy and radiotherapy, a total of 4 laryngectomies (8.0%) were necessary for persistent or locally recurrent disease. Only 2 (4.0%) patients required a tracheostomy, 4 (8.0%) had a feeding tube, and 1 (2.0%) patient had both at 1 year. For these patients, the functional larynx preservation rate was 78%. For the 71 patients assigned to neoadjuvant chemotherapy for bioselection, 11 laryngectomies (15.5%) were necessary after a poor response to induction chemotherapy and 13 total laryngectomies (18.3%) were necessary after completing chemoradiotherapy. Thus, 47 (66.2%) of the patients undergoing the neoadjuvant bioselective approach achieved organ preservation. For these patients, 4 (8.5%) had only a feeding gastrostomy tube, 4 (8.5%) had only a tracheostomy, and 5 (10.6%) patients had both at 1 year after treatment. In 34 of 71 patients, the functional organ preservation (neither tracheostomy nor gastrostomy tube) rate was 47.9%. Overall larynx preservation was achieved in 100 of 153 (65.3%) patients with advanced disease. Functional larynx preservation, including primary surgery for the entire advanced disease cohort, occurred in 78 (50.0%) of the 153 patients.
Timing of Total Laryngectomy
We were interested in exploring whether the timing of salvage or primary total laryngectomy as part of an overall treatment plan influenced outcome. Even though the numbers of patients undergoing total laryngectomy for advanced cancer were small, when the timing of total laryngectomy was analyzed, it was clear that OS and DSS favored the 11 patients with planned laryngectomy who were selected for laryngectomy after neoadjuvant chemotherapy compared with the 26 patients who underwent primary total laryngectomy or the 13 patients who required a delayed salvage laryngectomy after chemoradiotherapy. There were no failures (100% OS and DSS) Abbreviations: ACE, Adult Comorbidity Evaluation; HR, hazard ratio; OS, overall survival.
a The ACE-27 grades specific diseases and conditions into 1 of 3 levels of comorbidity: grade 1 (mild), grade 2 (moderate), or grade 3 (severe), according to the severity of individual organ decompensation and prognostic effect. Once the patient's individual diseases or comorbid conditions were classified, an overall comorbidity score (none, mild, moderate, or severe) was assigned based on the highest ranked single ailment. In the cases in which 2 or more moderate ailments occurred in different organ systems or disease groupings, the overall comorbidity score was designated as severe. among the patients undergoing planned laryngectomies performed as part of neoadjuvant bioselection. Overall survival and DSS rates were similar for patients undergoing initial total laryngectomy (n = 26) or late salvage laryngectomy after chemoradiotherapy (n = 13). Even though there was likely a negative selection bias for patients undergoing primary laryngectomy (ie, more advanced disease, such as T4a category glottic or medical contraindications to chemotherapy), there were no significant differences in DSS when comparing initial planned total laryngectomy (n = 26) with the entire group of patients requiring secondary total laryngectomy after neoadjuvant or concurrent chemoradiotherapy (n = 24).
Discussion
Controversy exists regarding the optimal treatment approach for patients with advanced laryngeal cancer. Organpreserving surgery and combinations of chemotherapy with radiotherapy as alternatives to total laryngectomy have been popularized to promote preservation of laryngeal function in patients with advanced disease. However, results of randomized clinical trials of surgical vs nonsurgical approaches have failed to show significant improvements in DSS or OS or clear superiority of 1 approach over another. 14,24,31,32 Despite this, concurrent chemoradiotherapy approaches have been widely adopted based on the desire for larynx preservation and evidence from meta-analyses that concurrent chemoradiotherapy is superior to radiotherapy alone and may also be superior to neoadjuvant or sequential chemotherapy combined with radiotherapy. 20-22 Unfortunately, both surgical and nonsurgical approaches have resulted in reported 5-year DSS rates of less than 50%. Although larynx preservation rates with concurrent chemoradiotherapy are typically higher than those achieved with a sequential approach, 17,24 no organ preservation approach has resulted in survival rates superior to those with total laryngectomy. There are also concerns that longterm toxic effects, cost, and treatment-related deaths may be greater compared with total laryngectomy. 10, 11 In addition, survival results of patients enrolled in carefully controlled clinical trials of chemoradiotherapy may not be generalizable to a nonselect population of patients or reproduced outside of clinical trial settings.
12,33
The objective of the present study was to analyze longterm survival outcomes for an unselected prospective patient cohort treated at a single institution that used an individualized treatment selection approach. Uniquely, our treatment selection algorithm incorporated the biological tumor response to a single cycle of neoadjuvant chemotherapy to select definitive treatment for patients with advanced laryngeal cancer. This approach was based on our group's successful earlier phase 2 clinical trial results. 26, 27 The findings from the present nonrandomized, observational cohort clearly demonstrate that the individualized treatment selection incorporating appropriate primary and salvage surgery in patients with advanced laryngeal cancer can achieve high longterm survival rates that are similar to those achieved in patients with more limited disease and are superior to the results of other retrospective studies or randomized clinical trials. This improved survival was accompanied by a high overall rate of functional larynx preservation. The results also confirm 5-year DSS approximating 80%, which is consistent with our group's previous phase 2 clinical trials initiated in the early 1990s.
26,27
The present results represent an important validation in a patient population that was not restricted by clinical trial eligibility criteria and included some patients receiving definitive chemoradiotherapy at nonacademic referral institutions but with treatment managed and followed up by our head and neck oncology team. These results compare favorably with those of a recent, large, single institutional cohort study comparing surgical with nonsurgical approaches in 235 patients with advanced supraglottic cancers that reported a 5-year survival rate of only 52% in both the surgical and nonsurgical groups.
34
Other large series and randomized clinical trials consistently report similar poor OS rates that range from 40% to 60%. 4, 24, [35] [36] [37] [38] The most recent SEER data comparing a surgical with a nonsurgical approach in 5394 patients from 1992 to 2009 reported a 5-year DSS of 55% for surgery and 51% for nonsurgical treatment and only 44% and 39% OS, respectively. 4 A more recent analysis of 6797 patients from 2004 to 2012 also showed a DSS in the range of 60%. 6 We believe the reason for the favorable results achieved in the present study are owing to better treatment selection, although other reasons, such as the experience of the treatment team and careful follow-up, could also be factors since early diagnosis and salvage of local tumor recurrences and treatment in an academic center have been associated with better survival, especially for complicated treatment.
35,38,39
The debate between primary total laryngectomy vs concurrent or neoadjuvant chemoradiotherapy has not been resolved. 10, 31, 32 Most studies document higher survival rates with primary surgery but at the sacrifice of laryngeal function. Furthermore, most chemoradiotherapy studies indicate no survival benefit with the addition of multicycle neoadjuvant chemotherapy. 19, 20, 22, 40 Our approach differs in that it incorporated a selection of patients for surgery using a single cycle of neoadjuvant chemotherapy for treatment selectionnot for a therapeutic benefit. Univariate Cox proportional hazards regression analysis with respect to primary treatment showed that both primary surgery and neoadjuvant bioselection had significantly improved OS and DSS compared with definitive chemoradiotherapy. The neoadjuvant bioselection and primary surgery groups showed similar DSS. In multivariable analysis adjusting for confounding prognostic factors, similar results were found. Because survival outcomes of our overall patient cohort looked better with a primary surgical approach across all tumor stages, we were interested in analyzing the HRs for all 3 treatment approaches in the advanced disease group. Relatively small sample sizes in these comparisons are reflected in the 95% CIs. To account for differences in patient and tumor characteristics and potential patient selection bias, we performed propensity score-adjusted Cox proportional hazards regression model analyses. In these analyses, OS and DSS were significantly improved in the neoadjuvant bioselection group over definitive chemoradiotherapy and radiotherapy.
Likewise, primary surgery was superior to both chemoradiotherapy and neoadjuvant bioselection for DSS; however, OS outcomes were similar for primary surgery and neoadjuvant bioselection. Others have applied such propensity analyses to SEER data comparing surgery with chemoradiotherapy and showed that survival outcomes did not differ significantly when patients with T4a category cancer were excluded. 37 Because few institutions use neoadjuvant bioselection, we performed an additional stratified Cox proportional hazards regression analysis to further compare the results of primary surgery with those of primary chemoradiotherapy after excluding the neoadjuvant bioselection group. Results of that analysis showed that primary surgical treatment was associated with a significantly reduced risk of death from cancer compared with concurrent chemoradiotherapy. These findings are consistent with others in the literature 6, 37 and underscore the important role that primary surgery should play in treatment selection for patients with advanced, particularly T4a category, cancer. Our results support the suggestion that careful selection criteria matching tumor and patient characteristics to treatment can enhance OS rates. The findings in this unselected series of patients with advanced cancers (stages III and IV) suggest that using tumor response to a single cycle of neoadjuvant chemotherapy as bioselection for definitive therapy can contribute to an effective strategy for both nonresponding and responding patients. There were no failures among patients selected for laryngectomy after neoadjuvant chemotherapy, which contradicts the expected poor outcomes typically associated with nonresponders after several cycles of neoadjuvant chemotherapy. Responders who were subsequently treated with concurrent chemoradiotherapy also fared well, and although there were local recurrences requiring salvage laryngectomy, OS rates were very good and 66% of the patients were able to preserve their larynx. Functional larynx preservation rates were higher for the definitive chemoradiotherapy group, but at a cost of decreased DSS. Nearly all chemoradiotherapy trials for patients with advanced cancers document a 60% to 70% success rate for organ preservation but at a cost of toxic effects, impairments in swallowing function, and suspected late toxic effects, including chronic aspiration. These toxic effects appear to be associated with larger initial tumor volumes and with radiation effects that are intensified by chemotherapy. Tumor volume has also been implicated as an important prognostic factor in chemoradiotherapy treatment of advanced laryngeal cancer and as a less important factor in surgical management. 41, 42 Poor outcomes associated with large tumor volumes have led to a re-emphasis on use of primary total laryngectomy with appropriate voice rehabilitation as a good treatment alternative, particularly in patients with extensive T4a cancers, since swallowing function after treatment is often better and quality-of-life outcomes frequently are similar to those of larynx preservation. 15, 43, 44 In fact, T4a category cancers are often considered to be a contraindication for chemoradiotherapy. 10 Most retrospective studies suggest better survival rates for patients with T4a category larynx cancer treated with surgery compared with chemoradiotherapy. 6,13,44-46 Our group's previous work demonstrated survival rates for patients with T4a category cancers that were similar to those achieved in patients with T3 category cancers when neoadjuvant bioselection was used with excellent preservation of speech and swallowing function. 27,47 Our present study is limited, however, by not allowing direct, randomized comparison of the various treatment approaches or prospective quality-of-life assessments other than the accepted measure of presence of tracheostomy or gastrostomy feeding tube reflecting laryngeal function. 48 Our group's prior work 15, 47 and that of others 43, 49 have suggested similar quality-of-life outcomes between primary laryngectomy and chemoradiotherapy survivors. When patients are asked about their treatment preferences, most opt for chemoradiotherapy; however, if survival differences favor surgery and quality-of-life outcomes are poor with chemoradiotherapy, an increasing number of patients will select surgery.
50
The rate of salvage laryngectomy (22%) was higher for patients receiving chemoradiotherapy after neoadjuvant bioselection compared with primary chemoradiotherapy (8%). This finding was likely due to the larger number of patients with T4a category cancer undergoing neoadjuvant bioselection and closer follow-up and more frequent salvage surgery compared with the primary chemoradiotherapy group. Despite the higher number of salvage laryngectomie, OS and DSS for the neoadjuvant bioselection group was superior to the survival in the definitive chemoradiotherapy group and compared favorably with outcomes in patients treated with primary surgery. The worst DSS results were noted for patients treated with primary chemoradiotherapy, suggesting that lack of selection may have delayed appropriate surgery for some patients or perhaps other confounding negative factors associated with combined therapy, such as longer overall treatment times or accelerated repopulation. [51] [52] [53] It is unlikely that negative patient selection was responsible the poorer results with definitive chemoradiotherapy since the most medically compromised patients or those with very advanced disease were likely selected for primary surgery and most patients with T4a category disease underwent bioselection. Patients who received laryngectomy-both primary and salvage laryngectomy-did well overall, supporting the continued important role of surgery in the treatment of patients with advanced laryngeal cancer. Communicating these various nuances in outcomes, quality of life, and long-term morbidity to the patient is one of the most challenging issues in patient management and treatment selection. Clearly, patient desires and expected speech and swallowing outcomes must be considered and may have greater importance than the treatment.
The major objective of neoadjuvant bioselection is to improve survival for all patients by matching an appropriate therapeutic approach to tumor biology. Not all patients benefit from chemotherapy and not all surgical patients achieve excellent survival. Clearly, trying to identify those who would benefit from each approach has obvious advantages that can translate into improved survival. The present results confirm our group's prior work 26, 27 and the findings of others that have adopted this approach 54 even for patients with T4a category primary tumors. We relied on clinical estimates of tumor response after chemotherapy to decide between surgery and chemoradiotherapy. It has been our experience that the most chemosensitive tumors respond dramatically and rapidly to ers for selecting patients for larynx preservation and thereby avoiding inherent toxic effects of chemotherapy. Our groups have shown that clinical tumor response assessment is probably better than relying on computed tomographic imaging, 58 while other studies suggest that changes in positron emission tomography imaging values may better reflect tumor response than either clinical or computed tomographic measures. 54 What is clear is that the optimal method to assess chemotherapy or radiotherapy sensitivity to select appropriate treatment has not yet been defined. Our group's prior studies of molecular biomarkers and neoadjuvant chemotherapy suggested that measures generally reflecting tumor aggressiveness and proliferation, such as overexpression of p53, proliferating cell nuclear antigen, cyclin D1, or vascular endothelial growth factor, or aggressive histologic pattern of invasion correlate with a favorable response to chemotherapy.
59-66
Markers of immune response, such as elevated peripheral blood CD4 + -positive T lymphocyte levels or high levels of tumorinfiltrating T cells have also shown promise as biomarkers.
56,67
Combining several markers has been more promising than single marker correlations. 56 Validation of previously suggested molecular biomarkers has not yet been performed in our patient cohort. Tissue microarrays have been constructed including some, but not all, of the cohort and should provide an important resource for exploring correlations of gene expression, tumor-infiltrating lymphocyte levels, and other biomarkers with chemotherapy response and survival outcomes.
Limitations
There are obvious limitations to the interpretation of differences by treatment in this cohort study. These limitations are primarily due to small sample sizes and a lack of randomization between treatment approaches. However, our patient inclusion was not limited by the strict eligibility criteria typically associated with clinical trials and patients were enrolled prospectively without bias by tumor site or stage. This population is more representative of real-life treatment situations and outcomes than a clinical trial cohort. Treatment decisions were uniformly applied by a skilled multidisciplinary team and follow-up was meticulous so that all patients were included in the analysis. These features are probable reasons why our results appear to be more favorable than those reported from SEER or National Cancer Database data where analysis by treatment may be confounded by inclusion of patients treated for palliation and outcomes and timing of salvage total laryngectomy may not be accurately recorded. In addition, analysis of tumor staging in SEER data are often inaccurate and rates of salvage laryngectomy are generally low. 37 We believe that our overall outcomes reflect the methods used to individualize treatment rather than just quality of care that might be attributed to an academic center with extensive experience. 39,68 Primary surgery and planned surgical salvage were critical components in our treatment of patients with advanced disease. Stage for stage, the best treatment strategy for maximizing patient survival and laryngeal function has not yet been identified. Although the OS rate for our entire cohort of patients was excellent, it was concerning to see OS of patients with T2N0 (stage II) cancers to be similar to that of patients with stage IV cancer (Figure 1) . Similar unsatisfactory survival rates for patients with T2 cancers have been reported recently in a large nationwide study of unselected patients in Finland. 69 To better understand these results, detailed analysis of our relatively small number of patients with T2 larynx cancer (N = 34) is under way. However, the results raise the question of whether understaging or undertreatment of patients with T2 cancer may be responsible for the declining survival rates for patients with intermediate disease as has been suggested in prior SEER data analysis. 70,71 Primary surgical management for both patients with limited disease and those with advanced disease was confirmed as an important and highly effective treatment approach that must be considered in all personalized treatment recommendations. Consideration of primary surgery is critical when excellent voice restoration and swallowing function can be expected, particularly if survival trade-offs are not obvious.
Conclusions
Long-term survival outcomes in this large, nonrandomized, prospective cohort suggest the potential benefit of careful patient selection and matching patient and tumor characteristics to an individualized treatment approach for patients with advanced laryngeal cancer. Very high survival rates were achieved in patients who participated in a bioselective treatment approach using a single cycle of neoadjuvant chemotherapy. To our knowledge, these rates were higher than any previously reported rates for patients with advanced laryngeal cancer and were similar to OS rates achieved in patients with limited disease. Excellent survival rates were also achieved in patients selected for primary surgery and for concurrent chemoradiotherapy suggesting that the overall optimal treatment approach for patients with advanced laryngeal cancer has not yet been defined. The results also confirm prior studies indicating that the highest larynx preservation rates can be expected with a primary chemoradiotherapy approach, although with somewhat lower OS compared with primary surgery or neoadjuvant bioselection. All 3 treatment approaches have a place in management algorithms. Further work is needed to define clinically relevant predictive biomarkers for treatment and compare quality of life after treatment to help guide decision making. The ACE-27 grades specific diseases and conditions into 1 of 3 levels of comorbidity: grade 1 (mild), grade 2 (moderate), or grade 3 (severe), according to the severity of individual organ decompensation and prognostic effect. Once the patient's individual diseases or comorbid conditions were classified, an overall comorbidity score (none, mild, moderate, or severe) was assigned based on the highest ranked single ailment. In the cases in which 2 or more moderate ailments occurred in different organ systems or disease groupings, the overall comorbidity score was designated as severe. 
